Efficacy of convalescent plasma for treatment of COVID-19 in Uganda.
Efficacy of convalescent plasma for treatment of COVID-19 in Uganda.
复制标题
DOI：
10.1136/bmjresp-2021-001017
复制
发表时间：
2021-08
影响因子：
4.1
通讯作者：
Bazeyo W
中科院分区：
文献类型：
--
作者：
Kirenga B;Byakika-Kibwika P;Muttamba W;Kayongo A;Loryndah NO;Mugenyi L;Kiwanuka N;Lusiba J;Atukunda A;Mugume R;Ssali F;Ddungu H;Katagira W;Sekibira R;Kityo C;Kyeyune D;Acana S;Aanyu-Tukamuhebwa H;Kabweru W;Nakwagala F;Bagaya BS;Kimuli I;Nantanda R;Buregyeya E;Byarugaba B;Olaro C;Mwebesa H;Joloba ML;Siddharthan T;Bazeyo W
Convalescent plasma (CCP) has been studied as a potential therapy for COVID-19, but data on its efficacy in Africa are limited. In this trial we set out to determine the efficacy of CCP for treatment of COVID-19 in Uganda. Patients with a positive SARS-CoV-2 reverse transcriptase (RT)-PCR test irrespective of disease severity were hospitalised and randomised to receive either COVID-19 CCP plus standard of care (SOC) or SOC alone. The primary outcome was time to viral clearance, defined as having two consecutive RT-PCR-negative tests by day 28. Secondary outcomes included time to symptom resolution, clinical status on the modified WHO Ordinal Clinical Scale (≥1-point increase), progression to severe/critical condition (defined as oxygen saturation <93% or needing oxygen), mortality and safety. A total of 136 patients were randomised, 69 to CCP+SOC and 67 to SOC only. The median age was 50 years (IQR: 38.5–62.0), 71.3% were male and the median duration of symptom was 7 days (IQR=4–8). Time to viral clearance was not different between the CCP+SOC and SOC arms (median of 6 days (IQR=4–11) vs 4 (IQR=4–6), p=0.196). There were no statistically significant differences in secondary outcomes in CCP+SOC versus SOC: time to symptom resolution (median=7 (IQR=5–7) vs 7 (IQR=5–10) days, p=0.450), disease progression (9 (22.0%) vs 7 (24.0%) patients, p=0.830) and mortality (10 (14.5%) vs 8 (11.9%) deaths, p=0.476). In this African trial, CCP therapy did not result in beneficial virological or clinical improvements. Further trials are needed to determine subgroups of patients who may benefit from CCP in Africa. Trial registration number NCT04542941.
登录
查看更多内容
DOI：
10.1126/science.aaf1279
发表时间：
2016-05-20
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Lu CL;Murakowski DK;Bournazos S;Schoofs T;Sarkar D;Halper-Stromberg A;Horwitz JA;Nogueira L;Golijanin J;Gazumyan A;Ravetch JV;Caskey M;Chakraborty AK;Nussenzweig MC
通讯作者：
Nussenzweig MC
非药物干预措施对130个国家和地区的SARS-COV-2传播的影响。
影响因子：
9.3
作者：
Liu Y;Morgenstern C;Kelly J;Lowe R;CMMID COVID-19 Working Group;Jit M
通讯作者：
Jit M
DOI：
10.1097/bs9.0000000000000047
发表时间：
2020-07
期刊：
Blood science (Baltimore, Md.)
影响因子：
--
作者：
Dai W;Gu H;Hao S
通讯作者：
Hao S
DOI：
10.1007/s10096-004-1271-9
发表时间：
2005-01
期刊：
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
影响因子：
--
作者：
Cheng Y;Wong R;Soo YO;Wong WS;Lee CK;Ng MH;Chan P;Wong KC;Leung CB;Cheng G
通讯作者：
Cheng G
影响因子：
120.7
作者：
Li, Ling;Zhang, Wei;Liu, Zhong
通讯作者：
Liu, Zhong